Literature DB >> 6522440

Specificity of anti-leukotriene actions of nicardipine.

A M Lefer, I Leprán, D M Roth, J B Smith.   

Abstract

The calcium channel blocker, nicardipine (100 ng/ml) markedly antagonized the coronary vasoconstrictor effect of the peptide leukotrienes LTC4 and LTD4 on the isolated perfused cat coronary artery. However, nicardipine even at 300 ng/ml failed to antagonize the leukotriene induced contraction of either tracheal or pulmonary parenchymal strips from guinea pigs. However, at higher concentrations (i.e., 10 micrograms/ml), nicardipine inhibited the production of peptide leukotrienes from minced cat lung incubated in the presence of A23187. Thus, nicardipine exerts some selectivity in its anti-leukotriene actions.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6522440     DOI: 10.1016/s0031-6989(84)80079-x

Source DB:  PubMed          Journal:  Pharmacol Res Commun        ISSN: 0031-6989


  4 in total

1.  Vasoactive effects of eicosapentaenoic acid on isolated vascular smooth muscle.

Authors:  A Yanagisawa; A M Lefer
Journal:  Basic Res Cardiol       Date:  1987 Mar-Apr       Impact factor: 17.165

2.  The effect of nifedipine alone or combined with low dose acetylsalicyclic acid on endotoxin-induced pulmonary hypertension in the piglet.

Authors:  D Schranz; R G Huth; H Stopfkuchen; B K Jüngst
Journal:  Intensive Care Med       Date:  1988       Impact factor: 17.440

3.  Lipoxins A4 and B4: comparison of icosanoids having bronchoconstrictor and vasodilator actions but lacking platelet aggregatory activity.

Authors:  A M Lefer; G L Stahl; D J Lefer; M E Brezinski; K C Nicolaou; C A Veale; Y Abe; J B Smith
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

Review 4.  Nicardipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in the treatment of angina pectoris, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold
Journal:  Drugs       Date:  1987-04       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.